Cibus, Inc. (CBUS) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Cibus, Inc. and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBUS
Cibus, Inc.
$1.61HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.73HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — CBUS vs IMDX
growth of $100 · dividends reinvested · last 9yCBUS -99.7% (-47.6%/yr)IMDX -96.0% (-30.1%/yr)IMDX compounded faster over this window
Log scale — wide-divergence pair
CBUS IMDX
CBUS vs IMDX: by the numbers
- •CBUS is the larger company ($123M vs $120M market cap).
- •Both run net losses; CBUS's is the smaller (-2258.89% vs -2955.63% net margin).
- •IMDX grew revenue faster over the past five years (27.24% vs -34.28% CAGR).
Metrics side by side
Valuation
| Metric | CBUS | IMDX |
|---|---|---|
| P/S ratio | 28.27 | 72.02 |
| P/B ratio | 8.30 | N/A |
Profitability
| Metric | CBUS | IMDX |
|---|---|---|
| Gross margin | -62.76% | 11.17% |
| Operating margin | -1853.92% | -754.08% |
| Net margin | -2258.89% | -2955.63% |
| ROE | -663.38% | N/A |
| ROIC | -17.99% | -223.06% |
Growth (annualized)
| Metric | CBUS | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | -34.28% | 27.24% |
| Total return CAGR (5Y) | -59.70% | -44.39% |
Frequently asked
- Which has grown faster, CBUS or IMDX?
- Over the past five years, IMDX grew revenue faster — CBUS at a -34.28% CAGR versus IMDX at 27.24%.
- How have CBUS and IMDX total returns compared?
- Over the past 5 years, CBUS delivered -59.70% and IMDX delivered -44.39% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cibus ROEInsight Molecular Diagnostics ROECibus operating marginInsight Molecular Diagnostics operating marginCibus revenue growthInsight Molecular Diagnostics revenue growthCibus free cash flowInsight Molecular Diagnostics free cash flow
Cibus & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.